×
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
Short-Covering Begins In Big Lots 
Fed officials signal rates may head to 'restrictive' levels
Closing prices for crude oil, gold and other commodities
Agilent Technologies Is Bottoming But Don’t Buy It Yet
Dick’s Sporting Goods Falls Flat On Weak Guidance 
Stocks rise on Wall Street after Fed meeting minutes release
Davos gathering overshadowed by global economic worries
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
Short-Covering Begins In Big Lots 
Fed officials signal rates may head to 'restrictive' levels
Closing prices for crude oil, gold and other commodities
Agilent Technologies Is Bottoming But Don’t Buy It Yet
Dick’s Sporting Goods Falls Flat On Weak Guidance 
Stocks rise on Wall Street after Fed meeting minutes release
Davos gathering overshadowed by global economic worries
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
Short-Covering Begins In Big Lots 
Fed officials signal rates may head to 'restrictive' levels
Closing prices for crude oil, gold and other commodities
Agilent Technologies Is Bottoming But Don’t Buy It Yet
Dick’s Sporting Goods Falls Flat On Weak Guidance 
Stocks rise on Wall Street after Fed meeting minutes release
Davos gathering overshadowed by global economic worries
S&P 500   3,978.73
DOW   32,120.28
QQQ   291.26
Short-Covering Begins In Big Lots 
Fed officials signal rates may head to 'restrictive' levels
Closing prices for crude oil, gold and other commodities
Agilent Technologies Is Bottoming But Don’t Buy It Yet
Dick’s Sporting Goods Falls Flat On Weak Guidance 
Stocks rise on Wall Street after Fed meeting minutes release
Davos gathering overshadowed by global economic worries
OTCMKTS:ATMS

Artemis Therapeutics (ATMS) Stock Forecast, Price & News

$3.20
+0.26 (+8.84%)
(As of 05/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.93
▼
$3.22
50-Day Range
$0.75
▼
$3.90
52-Week Range
$0.55
▼
$7.02
Volume
3,450 shs
Average Volume
4,736 shs
Market Capitalization
$16.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.96
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive ATMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Artemis Therapeutics logo

About Artemis Therapeutics

Artemis Therapeutics Inc. does not have significant operations. Previously, it was involved in the development of agents for the prevention and treatment of severe and life-threatening infectious diseases. The company is based in New York, New York. Artemis Therapeutics Inc. is a subsidiary of Tonak Ltd.

Headlines

May 6, 2022 | msn.com
Washington plays key role In NASA's Artemis missions
July 8, 2021 | in.finance.yahoo.com
Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma
April 30, 2021 | in.finance.yahoo.com
LendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive Year
April 30, 2021 | ca.finance.yahoo.com
Caution: Most Stocks Fail! Do This to Build a Winning Stock Portfolio
April 29, 2021 | au.finance.yahoo.com
Essex Communities Announces New Leadership Structure to Accommodate Rapid Growth
April 29, 2021 | au.finance.yahoo.com
‘The Falcon and Winter Soldier’ fails to pay off on its initial promise
November 18, 2020 | seekingalpha.com
Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside
January 21, 2019 | finance.yahoo.com
Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections
January 21, 2019 | finance.yahoo.com
New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
January 21, 2019 | finance.yahoo.com
Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication
January 21, 2019 | finance.yahoo.com
Artemis Therapeutics Announces Two Recent Publications Highlighting Artemisone's Activity Against Human Cytomegalovirus And Malaria
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Miscellaneous chemical products
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ATMS
Previous Symbol
CUSIP
N/A
CIK
1062128
Web
www.artemis-therapeutics.com
Phone
(646) 233-1454
Fax
800-253-5177
Employees
1
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.10) per share
Price / Book
-32.00

Profitability

EPS (Most Recent Fiscal Year)
($0.04)
Net Income
$-170 thousand
Net Margins
N/A
Pretax Margin
-557.58%
Return on Equity
N/A
Return on Assets
-1,237.04%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.01
Quick Ratio
0.01

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
5,154,000
Free Float
4,770,000
Market Cap
$16.49 million
Optionable
Not Optionable

Company Calendar

Today
5/26/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Artemis Therapeutics (OTCMKTS:ATMS) Frequently Asked Questions

Who are Artemis Therapeutics' key executives?
Artemis Therapeutics' management team includes the following people:
  • Mr. Chanan Morris, Chief Financial Officer (Age 56, Pay $42k)
  • Mr. Brian M. Culley M.A., M.B.A., Chief Exec. Officer (Age 51)
  • Dr. Dana Wolf M.D., Ph.D., Chief Medical Officer (Age 65)
What is Artemis Therapeutics' stock symbol?

Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?

Shares of ATMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Artemis Therapeutics' stock price today?

One share of ATMS stock can currently be purchased for approximately $3.20.

How much money does Artemis Therapeutics make?

Artemis Therapeutics has a market capitalization of $16.49 million. The company earns $-170 thousand in net income (profit) each year or ($0.04) on an earnings per share basis.

How many employees does Artemis Therapeutics have?

Artemis Therapeutics employs 1 workers across the globe.

What is Artemis Therapeutics' official website?

The official website for Artemis Therapeutics is www.artemis-therapeutics.com.

How can I contact Artemis Therapeutics?

Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The company can be reached via phone at (646) 233-1454, via email at [email protected], or via fax at 800-253-5177.

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.